1. Home
  2. BTE vs CADL Comparison

BTE vs CADL Comparison

Compare BTE & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Baytex Energy Corp

BTE

Baytex Energy Corp

HOLD

Current Price

$5.13

Market Cap

3.6B

ML Signal

HOLD

Logo Candel Therapeutics Inc.

CADL

Candel Therapeutics Inc.

HOLD

Current Price

$7.90

Market Cap

578.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTE
CADL
Founded
1993
1999
Country
Canada
United States
Employees
N/A
55
Industry
Meat/Poultry/Fish
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
578.8M
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
BTE
CADL
Price
$5.13
$7.90
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$19.00
AVG Volume (30 Days)
20.8M
2.2M
Earning Date
05-07-2026
05-14-2026
Dividend Yield
1.28%
N/A
EPS Growth
N/A
58.62
EPS
N/A
N/A
Revenue
N/A
$125,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$7.93
N/A
P/E Ratio
$18.43
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.58
$4.35
52 Week High
$5.36
$9.27

Technical Indicators

Market Signals
Indicator
BTE
CADL
Relative Strength Index (RSI) 59.40 57.78
Support Level $3.94 $4.91
Resistance Level $5.24 $9.27
Average True Range (ATR) 0.17 0.69
MACD -0.00 -0.11
Stochastic Oscillator 61.42 49.82

Price Performance

Historical Comparison
BTE
CADL

About BTE Baytex Energy Corp

Baytex Energy Corp is an oil and gas company. Geographically, the group operates in Canada and the United States. The company derives a majority of revenue from Canada. Its Canada segment includes the exploration, development, and production of crude oil and natural gas in Western Canada.

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Share on Social Networks: